Hyperion Therapeutics Announces First Quarter 2014 Financial Results

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BRISBANE, Calif., May 6, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $19.5 million for the first quarter of 2014 from the sales of its two products for the treatment of urea cycle disorders, RAVICTI® (glycerol phenylbutyrate) Oral Liquid and BUPHENYL® (sodium phenylbutyrate) Tablets and Powder. Adjusted net income for the first quarter 2014 was $3.8 million compared to an adjusted net loss of $8.5 million in the first quarter of 2013, an increase of $12.3 million. Hyperion ended the first quarter of 2014 with cash, cash equivalents and investments of $124.5 million.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC